Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Olema Pharmaceuticals ( (OLMA) ) is now available.
On October 18, 2025, Olema Pharmaceuticals announced new data from its Phase 1b/2 trial of palazestrant in combination with ribociclib for patients with ER+/HER2- advanced or metastatic breast cancer. The trial results showed encouraging activity with a median progression-free survival of 15.5 months in the 120 mg palazestrant cohort and demonstrated a favorable safety profile. These findings support the ongoing Phase 3 OPERA-02 trial and suggest the potential of palazestrant as a new standard of care in metastatic breast cancer, highlighting its efficacy in both ESR1 mutant and wild-type tumors.
The most recent analyst rating on (OLMA) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Olema Pharmaceuticals stock, see the OLMA Stock Forecast page.
Spark’s Take on OLMA Stock
According to Spark, TipRanks’ AI Analyst, OLMA is a Neutral.
Olema Pharmaceuticals faces substantial financial challenges with zero revenue and increasing losses, necessitating external funding. The technical analysis indicates some recent positive momentum, but the stock remains speculative due to negative profitability. The strategic collaboration with Novartis offers a positive outlook, potentially enhancing market position and supporting long-term growth. These factors collectively result in a moderate overall stock score.
To see Spark’s full report on OLMA stock, click here.
More about Olema Pharmaceuticals
Olema Pharmaceuticals, Inc., also known as Olema Oncology, is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for breast cancer. The company is advancing a pipeline of novel therapies, including its lead product candidate, palazestrant (OP-1250), a complete estrogen receptor antagonist and selective estrogen receptor degrader, currently in Phase 3 clinical trials.
Average Trading Volume: 967,657
Technical Sentiment Signal: Buy
Current Market Cap: $642.4M
Learn more about OLMA stock on TipRanks’ Stock Analysis page.